Details for Patent: 9,829,495

Which drugs does patent 9,829,495 protect, and when does it expire?

Patent 9,829,495 protects KORLYM and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 9,829,495

Title:	Method for differentially diagnosing ACTH-dependent Cushing's syndrome
Abstract:	This invention provides for an improved method for differentially diagnosing ACTH-dependent Cushing's syndrome. Current practice for differentially diagnosing ectopic ACTH syndrome and Cushing's Disease measures relative ACTH concentrations from the inferior petrosal venous sinus compared to fluid obtained from a periphery venous sample. This is performed before and after administration of exogenous corticotropin releasing factor, or after administration of metyrapone. This invention uses glucocorticoid receptor antagonists to induce release of endogenous CRH which stimulates ACTH to increase in patients with ectopic ACTH syndrome but not in those with Cushing's Disease.
Inventor(s):	Moraitis; Andreas G. (Menlo Park, CA)
Assignee:	Corcept Therapeutics, Inc. (Menlo Park, CA)
Application Number:	15/236,015
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,829,495
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,829,495

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Corcept Therap	KORLYM	mifepristone	TABLET;ORAL	202107-001	Feb 17, 2012	AB	RX	Yes	Yes						TREATING CUSHING'S SYNDROME

International Family Members for US Patent 9,829,495

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016305092
Canada	2994422
European Patent Office	3335043
Spain	2865334
Hong Kong	1255714
Israel	257439